[1]杨倩,王灿.人参皂苷Rg3减轻帕金森病小鼠神经系统氧化应激损伤的作用机制[J].西部中医药,2024,37(09):25-29.[doi:10.12174/j.issn.2096-9600.2024.09.06]
　YANG Qian,WANG Can.The Mechanism of Action of Ginsenoside Rg3 for the Relief from Oxidative Stress Injury in the Nervous System of Mice with Parkinson′s Disease[J].Western Journal of Traditional Chinese Medicine,2024,37(09):25-29.[doi:10.12174/j.issn.2096-9600.2024.09.06]
点击复制

人参皂苷Rg3减轻帕金森病小鼠神经系统氧化应激损伤的作用机制
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年09期
页码:
25-29
栏目:
基础研究
出版日期:
2024-09-15

文章信息/Info

Title:
The Mechanism of Action of Ginsenoside Rg3 for the Relief from Oxidative Stress Injury in the Nervous System of Mice with Parkinson′s Disease
作者:
杨倩, 王灿
湖南省脑科医院神经内科，湖南 长沙 410002
Author(s):
YANG Qian, WANG Can
Department of Neurology, Hunan Brain Hospital, Changsha 410002, China
关键词:
帕金森病; 黑质纹状体; 氧化应激损伤; 人参皂苷Rg3; 小鼠; 动物实验
Keywords:
Parkinson's disease; substantia nigra striata; oxidative stress injury; ginsenoside Rg3; mice; animal experiment
分类号:
R277.7
DOI:
10.12174/j.issn.2096-9600.2024.09.06
文献标志码:
A
摘要:
目的探究人参皂苷Rg3减轻帕金森病（Parkinson′s disease，PD）小鼠神经系统氧化应激损伤的作用机制。 方法将60只C57BL/6小鼠分为对照组、PD组、低剂量干预组和高剂量干预组，每组15只。通过腹腔注射1-甲基-4-苯基-1，2，3，6-四氢吡啶（1-methy1-4-phenvl-1，2，3，6-tetrahvdropvridine，MPTP）构建PD小鼠模型，建模前3天，低、高剂量干预组小鼠分别腹腔注射3、12 mg/kg人参皂苷Rg3，造模后继续干预28天，对照组和PD组腹腔注射等量生理盐水。各组小鼠腹腔注射第4、8、12天时进行爬杆实验和旋转实验评估运动能力；末次腹腔注射完成后，断颈处死小鼠取脑组织制成冰冻切片，免疫组化分析黑质纹状体中酪氨酸羟化酶（tyrosine hydroxylase，TH）表达水平；酶联免疫吸附法测定黑质纹状体中超氧化物歧化酶（superoxide dismutase，SOD）、丙二醛（malondialdehyde，MDA）、谷胱甘肽过氧化物酶（glutathione peroxidase，GSH-PX）水平；Western blot方法检测黑质纹状体中TH、核因子E2相关因子2（nuclear factor erythroid 2-related factor 2，Nrf2）、血红素氧合酶1（heme oxygenase-1，HO-1）、醌氧化还原酶1（quinoneoxidoreductase 1，NQO1）蛋白表达水平。 结果与对照组比较，PD组小鼠爬杆时间延长、旋转停留时间缩短、MDA水平升高，TH阳性率、SOD、GSH-PX活性、TH、Nrf2、HO-1、NQO1蛋白水平均降低，差异有统计学意义（P＜0.05）；与PD组比较，低、高剂量干预组小鼠爬杆时间缩短，旋转停留时间延长，MDA水平降低，TH阳性率、SOD、GSH-PX活性、TH、Nrf2、HO-1、NQO1蛋白水平均升高，差异有统计学意义（P＜0.05）。 结论人参皂苷Rg3可能通过激活黑质纹状体中Nrf2/HO-1/NQO1通路，减轻PD小鼠神经系统氧化应激损伤，而改善其病理状态。
Abstract:
ObjectiveTo survey the mechanism of ginsenoside Rg3 alleviating oxidative stress injury in the nervous system of mice with Parkinson's disease (PD). MethodsSixty C57BL/6 mice were divided into the control group, PD group, low- dose intervention group and high-dose intervention group with 15 ones in each group. PD mice models were constructed using intraperitoneal injection of MPTP, the mice in the low-dose intervention group and high-dose intervention group were intraperitoneally injected with 3 and 12 mg/kg ginsenoside Rg3 respectively three days before the modeling, and intervened for 28 days after the modeling, the control group and PD group accepted abdominal injection of an equal amount of physiological saline. Motor ability was assessed by pole-climbing test and rotation experiment on the forth, eighth and 12th day of intraperitoneal injection in each group of mice; after completing the last intraperitoneal injection , mice were sacrificed by cervical dislocation and brain tissues were taken to make frozen sections, immunohistochemical analysis was carried out to detect the expressions of tyrosine hydroxylase (TH) in substantia nigra striata; ELISA was applied to measure the levels of SOD, MDA and GSH-PX; Western blot was used to measure the expressions of TH, Nrf-2, HO-1 and NQ01 protein in substantia nigra striata. ResultsCompared with the control group, pole-climbing time, rotation times, rotation time and the levels of MDA increased in the mice of PD group, while TH positive rate, the activity of SOD and GSH-PX, the levels of TH, Nrf2, HO-1 and NQ01 protein decreased, and the difference had statistical meaning (P<0.05); compared with PD group, pole-climbing time, rotation times, rotation time and the levels of MDA reduced in low and high dose intervention groups while TH positive rate, the activity of SOD and GSH-PX, the levels of TH, Nrf2, HO-1 and NQ01 protein increased, and the difference was statistically significant (P<0.05). ConclusionGinsenoside Rg3 could improve its pathological state possibly through activating Nrf2/HO-1/NQ01 pathway in substantia nigra striata and relieving oxidative stress injury of nervous system in PD mice.

相似文献/References:

[1]李敏,杨明会.补肾活血法治疗帕金森病患者30例临床研究*[J].西部中医药,2013,26(03):1.
　LIMin,YANGMinghui.ClinicalStudyonBuShenHuoXueMethodinTreating30CasesofPatientswithParkinson'sDisease[J].Western Journal of Traditional Chinese Medicine,2013,26(09):1.
[2]盛刚,郭珍△.针刺治疗帕金森病38例[J].西部中医药,2018,31(10):108.
　SHENG Gang,GUO Zhen.Acupuncture in Treating 38 Cases of Parkinson′s Disease[J].Western Journal of Traditional Chinese Medicine,2018,31(09):108.
[3]吴林,陈静,唐农,等.基于人体阴阳本体结构理论探讨帕金森病的治疗[J].西部中医药,2022,35(02):58.[doi:10.12174/j.issn.2096-9600.2022.02.15]
　WU Lin,CHEN Jing,TANG Nong,et al.The Therapy for Parkinson′s Disease on the Foundation of Ontology Structural Theory of Human Yin and Yang[J].Western Journal of Traditional Chinese Medicine,2022,35(09):58.[doi:10.12174/j.issn.2096-9600.2022.02.15]
[4]刘秋平,张雪竹.“三焦针法”治疗帕金森病患者快速动眼睡眠行为障碍思想探微[J].西部中医药,2021,34(05):130.[doi:10.12174/j.issn.2096-9600.2021.05.33]
　LIU Qiuping,ZHANG Xuezhu.Probe into the Thinking of Treating RBD in Parkinson's Disease Patient by “Triple Energizer Acupuncture”[J].Western Journal of Traditional Chinese Medicine,2021,34(09):130.[doi:10.12174/j.issn.2096-9600.2021.05.33]
[5]孙雪,梁建庆,何建成,等.帕金森病的中医辨证治疗[J].西部中医药,2021,34(02):131.[doi:10.12174/j.issn.2096-9600.2021.02.35]
　SUN Xue,LIANG Jianqing,HE Jiancheng,et al.TCM Syndrome Differentiation Treatment of Parkinson′s Disease[J].Western Journal of Traditional Chinese Medicine,2021,34(09):131.[doi:10.12174/j.issn.2096-9600.2021.02.35]
[6]王春玲,罗宁,文晓东,等.乌梅总黄酮通过线粒体自噬对帕金森病大鼠的保护作用[J].西部中医药,2022,35(12):72.[doi:10.12174/j.issn.2096-9600.2022.12.15]
　WANG Chunling,LUO Ning,WEN Xiaodong,et al.Protective Effects of Fructus Mume Total Flavone on Rat Model with Parkinson’s Disease Through Mitophagy[J].Western Journal of Traditional Chinese Medicine,2022,35(09):72.[doi:10.12174/j.issn.2096-9600.2022.12.15]
[7]孙雪,梁鹏,梁建庆,等.基于数据挖掘分析名老中医治疗帕金森病的临证经验[J].西部中医药,2024,37(03):32.[doi:10.12174/j.issn.2096-9600.2024.03.07]
　SUN Xue,LIANG Peng,LIANG Jianqing,et al.TCM Experts' Clinical Experience in Treating Parkinson's Disease based on Data Mining[J].Western Journal of Traditional Chinese Medicine,2024,37(09):32.[doi:10.12174/j.issn.2096-9600.2024.03.07]
[8]李庆,张慧,王逍,等.醒脑解郁胶囊治疗帕金森病合并抑郁30例[J].西部中医药,2024,37(06):125.[doi:10.12174/j.issn.2096-9600.2024.06.29]
　LI Qing,ZHANG Hui,WANG Xiao,et al.Treatment of Parkinson′s Disease Combined with Depression with Xingnao Jieyu Capsules: 30 Cases[J].Western Journal of Traditional Chinese Medicine,2024,37(09):125.[doi:10.12174/j.issn.2096-9600.2024.06.29]
[9]邓仙勇,梁健芬,张兴博,等.从中医肝脾肾论治帕金森病的研究进展[J].西部中医药,2024,37(10):82.[doi:10.12174/j.issn.2096-9600.2024.10.18]
　DENG Xianyong,LIANG Jianfen,ZHANG Xingbo,et al.Research Progress in the Treatment of Parkinson′s Disease from Liver, Spleen and Kidney in TCM[J].Western Journal of Traditional Chinese Medicine,2024,37(09):82.[doi:10.12174/j.issn.2096-9600.2024.10.18]

备注/Memo

备注/Memo:
杨倩（1983—），女，副主任医师。研究方向：中枢神经系统变性病的诊治。E-mail：jiaotangcha02@163.com。湖南省脑科医院科研基金课题（20201642）。
更新日期/Last Update: 2024-09-15